Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non–small-cell lung cancer (NSCLC), based on the importance of the signaling …

Background Combined inhibition of vascular, platelet-derived, and epidermal growth factor
receptor (EGFR) pathways may overcome refractoriness to single agents in platinum …

Purpose: This multicenter, phase II study evaluates the efficacy and safety of erlotinib, an
epidermal growth factor receptor (EGFR) inhibitor, plus sorafenib, a multityrosine kinase …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …

7001 Background: Sunitinib malate (SU11248) is an oral, multitargeted tyrosine kinase
inhibitor targeting VEGFR, PDGFR, KIT, FLT3 and RET on tumor cells, tumor neovasculature …

Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …

Purpose Aberrant vascular endothelial growth factor (VEGF) and platelet-derived growth
factor (PDGF) signaling have been shown to play a role in non–small-cell lung cancer …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …